Alzheimer's disease

The PBS subsidises medicines for patients with Alzheimer's disease.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with donepezil, rivastigmine, galantamine and memantine under the National Health Act 1953, section 85 for Alzheimer’s disease.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing Alzheimer’s medications.

Applications

Initial 1 treatment

Initial 1 applications can be requested for up to 2 months for each strength of each drug.

Apply for authority approval to prescribe Initial 1 PBS subsidised drug to treat patients with Alzheimer’s disease either through:

Initial 2 treatment

Initial 2 applications must be requested for the balance of up to 6 months initial treatment for each strength of drug.

Apply for authority approval to prescribe initial 2 PBS subsidised drug to treat patients with Alzheimer’s disease in writing either by:

All applications must include the completed:

Continuing treatment

Continuing treatment with PBS subsidised rivastigmine, galantamine and memantine are Authority Required (Streamlined). They do not require prior approval from Services Australia for the PBS listed quantity and repeats.

Further information

For more information contact us on the PBS authority approvals enquiry line.

Page last updated: 1 March 2020